Hematological Malignancies

Pipeline Programs

Companies

Clinical Trials

4 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

338%

Small Molecule

338%

Cell Therapy

225%

+ 17 programs with unclassified modality

Competitive Landscape

20 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Gamida CellIsrael - Kiryat Gat

3 programs

NiCord®Phase 31 trial

omidubicelPhase 3Cell Therapy1 trial

NiCord®Phase 1/21 trial

Active Trials

NCT01816230Completed36Est. Jun 2018

NCT02730299Completed125Est. Feb 2025

NCT04260698Completed36Est. May 2025

Sharp TherapeuticsPA - Pittsburgh

2 programs

Pembrolizumab/vibostolimab coformulationPhase 2

NemtabrutinibPhase 1Small Molecule

MSDIreland - Ballydine

2 programs

Pembrolizumab/vibostolimab coformulationPhase 21 trial

NemtabrutinibPhase 1Small Molecule1 trial

Active Trials

NCT05347225Active Not Recruiting12Est. Dec 2028

NCT05005442Completed192Est. Dec 2024

OtsukaJapan - Tokushima

1 program

Full intensity, double umbilical cord, stem cell transplantPhase 21 trial

Active Trials

NCT00763490Completed20Est. Oct 2015

AstraZenecaCAMBRIDGE, United Kingdom

1 program

AZD9829Phase 1/21 trial

Active Trials

NCT06179511Active Not Recruiting56Est. Mar 2026

Rhizen PharmaceuticalsSwitzerland - Basel

1 program

TenalisibPhase 1/2Small Molecule1 trial

Active Trials

NCT03711604Completed17Est. Mar 2023

Kangpu BiopharmaceuticalsChina - Shanghai

1 program

KPG-818Phase 11 trial

Active Trials

NCT04283097Completed30Est. Dec 2024

Kite PharmaCA - El Segundo

1 program

MagrolimabPhase 1Monoclonal Antibody

SandozAustria - Kundl

1 program

Study Part 1: KRP203Phase 1

Gilead SciencesFOSTER CITY, CA

2 programs

MagrolimabPHASE_1Monoclonal Antibody1 trial

MagrolimabPHASE_1Monoclonal Antibody

Active Trials

NCT03248479Terminated258Est. Sep 2023

Angel PharmaceuticalsChina - Zhejiang

1 program

Weighted BlanketN/A1 trial

Active Trials

NCT06584955Active Not Recruiting20Est. Jul 2027

HutchmedChina - Hong Kong

1 program

HMPL-506PHASE_11 trial

Active Trials

NCT06387082Recruiting132Est. Dec 2027

InnoCareChina - Beijing

1 program

ICP-248PHASE_11 trial

Active Trials

NCT05728658Recruiting191Est. Oct 2026

Karyopharm TherapeuticsNEWTON, MA

1 program

KPT-330PHASE_11 trial

Active Trials

NCT01607892Completed286Est. Oct 2015

CASI PharmaceuticalsBEIJING, China

1 program

MKC-1PHASE_11 trial

Active Trials

NCT00506402Completed30Est. Apr 2009

TevaIsrael - Petach Tikva

1 program

Obatoclax mesylatePHASE_14 trials

Active Trials

NCT00427856Completed7Est. Jul 2009

NCT00405951Completed47Est. Sep 2009

NCT00360035Completed22Est. Feb 2009

+1 more trials

NovartisBASEL, Switzerland

1 program

Study Part 1: KRP203PHASE_11 trial

Active Trials

NCT01830010Completed23Est. Aug 2018

Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang

1 program

TQB3820 tabletsPHASE_11 trial

Active Trials

NCT05020639Unknown116Est. Dec 2024

Daiichi SankyoChina - Shanghai

1 program

DS3790aPHASE_1_21 trial

Active Trials

NCT07220616Recruiting420Est. Nov 2030

Galapagos2800 MECHELEN, Belgium

1 program

GLPG CAR T-cell therapyPHASE_3Cell Therapy1 trial

Active Trials

NCT06652633Recruiting546Est. Jul 2039

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

GalapagosGLPG CAR T-cell therapy

Gamida Cellomidubicel

Gamida CellNiCord®

MSDPembrolizumab/vibostolimab coformulation

OtsukaFull intensity, double umbilical cord, stem cell transplant

TevaObatoclax mesylate

Daiichi SankyoDS3790a

AstraZenecaAZD9829

Rhizen PharmaceuticalsTenalisib

Gamida CellNiCord®

TevaObatoclax mesylate

HutchmedHMPL-506

InnoCareICP-248

MSDNemtabrutinib

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 2,666 patients across 23 trials

NCT06652633 GalapagosGLPG CAR T-cell therapy

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Start: Sep 2024Est. completion: Jul 2039546 patients

Phase 3Recruiting

NCT04260698 Gamida Cellomidubicel

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Start: Jul 2020Est. completion: May 202536 patients

Phase 3Completed

NCT02730299 Gamida CellNiCord®

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Start: Dec 2016Est. completion: Feb 2025125 patients

Phase 3Completed

NCT05005442 MSDPembrolizumab/vibostolimab coformulation

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Start: Sep 2021Est. completion: Dec 2024192 patients

Phase 2Completed

NCT00763490 OtsukaFull intensity, double umbilical cord, stem cell transplant

Trial Of Double Umbilical Cord Blood Transplantation

Start: Dec 2008Est. completion: Oct 201520 patients

Phase 2Completed

NCT00427856 TevaObatoclax mesylate

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Start: Mar 2007Est. completion: Jul 20097 patients

Phase 2Completed

NCT00360035 TevaObatoclax mesylate

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

Start: Jul 2006Est. completion: Feb 200922 patients

Phase 2Completed

NCT07220616 Daiichi SankyoDS3790a

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Start: Jan 2026Est. completion: Nov 2030420 patients

Phase 1/2Recruiting

NCT06179511 AstraZenecaAZD9829

Study of AZD9829 in CD123+ Hematological Malignancies

Start: Jan 2024Est. completion: Mar 202656 patients

Phase 1/2Active Not Recruiting

NCT03711604 Rhizen PharmaceuticalsTenalisib

Compassionate Use Study of Tenalisib (RP6530)

Start: Nov 2018Est. completion: Mar 202317 patients

Phase 1/2Completed

NCT01816230 Gamida CellNiCord®

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

Start: Apr 2013Est. completion: Jun 201836 patients

Phase 1/2Completed

NCT00405951 TevaObatoclax mesylate

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

Start: Oct 2006Est. completion: Sep 200947 patients

Phase 1/2Completed

NCT06387082 HutchmedHMPL-506

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Start: May 2024Est. completion: Dec 2027132 patients

Phase 1Recruiting

NCT05728658 InnoCareICP-248

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Start: Mar 2023Est. completion: Oct 2026191 patients

Phase 1Recruiting

NCT05347225 MSDNemtabrutinib

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

Start: Jun 2022Est. completion: Dec 202812 patients

Phase 1Active Not Recruiting

NCT04283097 Kangpu BiopharmaceuticalsKPG-818

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Start: Sep 2021Est. completion: Dec 202430 patients

Phase 1Completed

NCT05020639 Chia Tai TianQing Pharmaceutical GroupTQB3820 tablets

A Study of TQB3820 in Patients With Hematological Malignancies

Start: Aug 2021Est. completion: Dec 2024116 patients

Phase 1Unknown

NCT03248479 Gilead SciencesMagrolimab

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Start: Sep 2017Est. completion: Sep 2023258 patients

Phase 1Terminated

NCT01830010 NovartisStudy Part 1: KRP203

A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Start: Jun 2013Est. completion: Aug 201823 patients

Phase 1Completed

NCT01607892 Karyopharm TherapeuticsKPT-330

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Start: Jul 2012Est. completion: Oct 2015286 patients

Phase 1Completed

NCT00506402 CASI PharmaceuticalsMKC-1

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Start: Nov 2006Est. completion: Apr 200930 patients

Phase 1Completed

NCT00438178 TevaObatoclax mesylate

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

Start: Oct 200544 patients

Phase 1Completed

NCT06584955 Angel PharmaceuticalsWeighted Blanket

Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies

Start: May 2025Est. completion: Jul 202720 patients

N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

4 actively recruiting trials targeting 2,666 patients

20 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.